缺血性卒中伴皮质表面铁沉积患者随访期间的卒中风险与抗血栓治疗
本研究回顾性分析MICON数据库12669例近期缺血性卒中或短暂性脑缺血发作患者,其中273例(2.2%)存在皮质表面铁沉积(cSS)。随访期间cSS与任何卒中风险升高相关(调整HR 1.62),单独抗血小板或抗凝治疗时缺血性卒中风险高于颅内出血,但联合抗血栓治疗时颅内出血风险显著升高。
要点
- cSS患者随访期间任何卒中风险升高(调整HR 1.62,95%CI 1.14-2.28)。
- 单独抗血小板或抗凝治疗时,cSS患者缺血性卒中风险高于颅内出血。
- cSS患者联合抗血小板和抗凝治疗时颅内出血风险显著升高(调整HR 13.26)。
核心结论
- 近期缺血性卒中或TIA伴cSS患者随访期间任何卒中风险升高,单独抗血小板或抗凝治疗时缺血性卒中风险超过颅内出血风险,但联合抗血栓治疗时颅内出血风险超过缺血性卒中风险。
- 作者认为,cSS患者不应避免单独抗血小板或抗凝治疗,但联合抗血栓治疗可能有害;该发现需随机临床试验证实。
研究设计与样本
- 回顾性分析微出血国际协作网络(MICON)数据库,纳入近期缺血性卒中或TIA且具有MRI评估cSS、抗血栓治疗及复发脑血管事件和死亡数据的患者,共12669例(平均年龄70.4±12.3岁,57.3%男性),其中cSS 273例(2.2%)。
主要发现
- 平均随访24±17个月,cSS组缺血性卒中发生率57.1/1000人年 vs 颅内出血14.6/1000人年,非cSS组分别为33.7/1000人年 vs 6.3/1000人年。
- cSS组任何卒中发生率83/1000人年 vs 非cSS组42/1000人年,调整HR 1.62(95%CI 1.14-2.28,p=0.006)。
- 在抗血小板治疗亚组(n=6554)或抗凝治疗亚组(n=4044)中,cSS与任何卒中的关联不显著。
- cSS患者联合抗血小板和抗凝治疗(n=1569)相比非cSS组,颅内出血发生率107.5/1000人年 vs 4.9/1000人年,调整HR 13.26(95%CI 2.90-60.63,p=0.001);任何卒中发生率198.8/1000人年 vs 34.7/1000人年,调整HR 5.03(95%CI 2.03-12.44,p<0.001)。
临床怎么用
- 作者建议,cSS患者不应避免单独抗血小板或抗凝治疗,但联合抗血栓治疗可能有害;该建议需随机临床试验证实。
局限性
- 原文未报告局限性,但作者指出发现需随机临床试验证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: In patients with ischemic stroke (IS) or transient ischemic attack (TIA) and cortical superficial siderosis (cSS), there are few data regarding the risk of future cerebrovascular events and also about the benefits and safety of antithrombotic drugs for secondary prevention. We investigated the associations of cSS and stroke risk in patients with recent IS or TIA. METHODS: We retrospectively analyzed the Microbleeds International Collaborative Network (MICON) database. We selected patients with IS or TIA from cohorts who had MRI-assessed cSS, available data on antithrombotic treatments, recurrent cerebrovascular events (intracranial hemorrhage [ICrH], IS, or any stroke [ICrH or IS]), and mortality. We calculated incidence rates (IRs) and performed univariable and multivariable Cox regression analyses. RESULTS: Of 12,669 patients (mean age 70.4 ± 12.3 years, 57.3% men), cSS was detected in 273 (2.2%) patients. During a mean follow-up of 24 ± 17 months, IS was more frequent than ICrH in both cSS (IR 57.1 vs 14.6 per 1,000 patient-years) and non-cSS (33.7 vs 6.3 per 1,000 patient-years) groups. Compared with the non-cSS group, cSS was associated with any stroke on multivariable analysis {IR 83 vs 42 per 1,000 patient-years, adjusted hazard ratio [HR] for cSS 1.62 (95% CI: 1.14-2.28; p = 0.006)}. This association was not significant in subgroups of patients treated with antiplatelet drugs (n = 6,554) or with anticoagulants (n = 4,044). Patients with cSS who were treated with both antiplatelet drugs and anticoagulants (n = 1,569) had a higher incidence of ICrH (IR 107.5 vs 4.9 per 1,000 patient-years, adjusted HR 13.26; 95% CI: 2.90-60.63; p = 0.001) and of any stroke (IR 198.8 vs 34.7 per 1,000 patient-years, adjusted HR 5.03; 95% CI: 2.03-12.44; p < 0.001) compared with the non-cSS group. DISCUSSION: Patients with IS or TIA with cSS are at increased risk of stroke (ICrH or IS) during follow-up; the risk of IS exceeds that of ICrH for patients receiving antiplatelet or anticoagulant treatment alone, but the risk of ICrH exceeds that of IS in patients receiving both treatments. The findings suggest that either antiplatelet or anticoagulant treatment alone should not be avoided in patients with cSS, but combined antithrombotic therapy might be hazardous. Our findings need to be confirmed by randomized clinical trials.
引用
- Martí-Fàbregas J, Camps-Renom P, Best JG, et al. Stroke Risk and Antithrombotic Treatment During Follow-up of Patients With Ischemic Stroke and Cortical Superficial Siderosis. Neurology. 2022. PMID: 36535778. doi:10.1212/WNL.0000000000201723
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。